Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why the Market is Punishing General Electric Stock

By Chris Lau, InvestorPlace Contributor

GE hired a strong CEO and is actively selling down assets. With a turnaround plan in place, why are investors selling General Electric stock?

LULU Stock Is Still a Little Too Pricey, but Watch for a Dip

By Chris Lau, InvestorPlace Contributor

Markets are selling LULU stock alongside other equities, without really thinking about Lululemon's 2019 growth potential.

Value Investors Should Buy into the Teva Stock Dip

By Chris Lau, InvestorPlace Contributor

Teva stock is now at yearly lows, a victim of negative macro news, falling stock markets, and year-end tax-loss selling.

Bristol-Myers Squibb Stock Is Coming Back Slow, but That’s Fine

By Chris Lau, InvestorPlace Contributor

Bristol-Myers Squibb stock took a hit in October. The stock is still rebounding, albeit slowly which makes it a good value.

Why Aphria Stock Isn’t the Kind of Pot Stock to Hold Forever

By Chris Lau, InvestorPlace Contributor

The euphoric rise in Aphria stock is history after increased bearishness, thanks to investor scrutiny over an acquisition, has beaten APHA down.

Load More